Association of Plasma Adipokines with Chronic Obstructive Pulmonary Disease Severity and Progression
Association of Plasma Adipokines with Chronic Obstructive Pulmonary Disease Severity and Progression
复制标题
DOI：
10.1513/annalsats.201501-005oc
复制
发表时间：
2015-07-01
影响因子：
8.3
通讯作者：
Park, Hye Yun
中科院分区：
文献类型：
--
作者：
Oh, Yeon-Mok;Jeong, Byeong-Ho;Park, Hye Yun
原理：两种脂肪因子，瘦素和脂联素，相互调节新陈代谢和炎症系统。脂联素在慢性阻塞性肺疾病(COPD)中的作用已有研究。目的：根据COPD的表型，探讨瘦素、脂联素及瘦素/脂联素比值与COPD严重程度及进展的关系。方法：对韩国阻塞性肺疾病队列中196例COPD患者的血浆瘦素、脂联素水平进行检测。采用线性回归模型和混合线性回归方法，分析血浆瘦素和脂联素水平及瘦素/脂联素比值与慢性阻塞性肺疾病严重程度和进展的关系。测量和主要结果：血浆脂联素浓度与初始CT显示的肺气肿百分比呈正相关(调整后P=0.022)，而血浆瘦素浓度和瘦素/脂联素比值与初始FEV1呈显著负相关(调整后瘦素P=0.013，调整后P=0.041)。血浆瘦素和瘦素/脂联素比值的升高与3年肺气肿百分比的变化显著相关(校正后的瘦素P=0.037，校正后的瘦素/脂联素比值P=0.029)，而这些脂肪因子与3年的FEV1下降无关。结论：血浆脂联素和瘦素随慢性阻塞性肺疾病的表型而异。血浆瘦素和瘦素/脂联素比值与CT评估的肺气肿的变化显著相关，但与脂联素无关，提示瘦素和瘦素/脂联素比值可能是COPD患者肺气肿进展的潜在生物标志物。
Rationale: Two adipokines, leptin and adiponectin, regulate metabolic and inflammatory systems reciprocally. The role of adiponectin in chronic obstructive pulmonary disease (COPD) has been studied. However, there are few data evaluating the relationship of plasma leptin with COPD severity or progression.Objectives: The objective of this study was to evaluate the relationship of leptin, adiponectin, and the leptin/adiponectin ratio with COPD severity and progression according to COPD phenotypes.Methods: Plasma leptin and adiponectin levels were measured in 196 subjects with COPD selected from the Korean Obstructive Lung Disease cohort. Using a linear regression model and mixed linear regression, we determined the relationship of plasma leptin and adiponectin levels and the leptin/adiponectin ratio to COPD severity and progression over 3 years.Measurements and Main Results: The concentration of adiponectin in plasma positively correlated with percent emphysema on initial computed tomography (CT) (adjusted P = 0.022), whereas plasma leptin concentrations and the leptin/adiponectin ratio exhibited a significant inverse correlation with initial FEV1 (adjusted P= 0.013 for leptin and adjusted P= 0.041 for leptin/adiponectin ratio). Increased plasma leptin and leptin/adiponectin ratio were significantly associated with change in percent emphysema over 3 years (adjusted P = 0.037 for leptin and adjusted P = 0.029 for leptin/adiponectin ratio), whereas none of the adipokines demonstrated an association with FEV1 decline over the 3-year period.Conclusions: Plasma adiponectin and leptin vary according to COPD phenotypes. Plasma leptin and the leptin/adiponectin ratio, but not adiponectin, were significantly associated with changes in CT-assessed emphysema, suggesting a potential role as a biomarker in emphysema progression in patients with COPD.